<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Surgery and Cancer</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D38F9D2A-2ACA-4693-A148-6046FE7AC2CA"><gtr:id>D38F9D2A-2ACA-4693-A148-6046FE7AC2CA</gtr:id><gtr:firstName>Victoria</gtr:firstName><gtr:surname>Harding</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FL000172%2F1"><gtr:id>B133AAAC-C0BD-4036-8B7A-84BE530D2CA1</gtr:id><gtr:title>The role of miRNAs in regulation and signalling induced by a new oncogenic kinase, LMTK3</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/L000172/1</gtr:grantReference><gtr:abstractText>Abnormalities in the function and amount of a protein called estrogen receptor-alpha (ERa) in tumor cells, is crucial to the development and growth of the majority of breast cancers. The ERa performs the functions of the hormone estrogen inside cells by stimulating the production of particular proteins called estrogen response elements, leading to cell growth and survival. While primary breast cancer is often treatable, once it spreads it is no longer curable and therefore researchers are constantly trying to find new genes and proteins in cancer cells that control their spread (metastasis) and cause resistance to current treatments, so we can cure more cancers. However, while a number of such genes have been discovered, the factors that regulate these often remain unclear and therefore these findings may not result in new treatments or benefits to patients. 
We have recently identified a new protein in breast cancer called LMTK3 and have shown that it acts directly and indirectly on pathways controlled by the ERa and is therefore crucial in causing breast cancer metastasis and resistance to hormone treatments. In fact, in a study of over 500 women with breast cancer we have shown that women whose breast cancers contain high levels of LMTK3 have a far greater risk of their cancer spreading, respond less well to treatment and die sooner than those with low levels of this protein. We therefore now aim to discover methods to successfully prevent LMTK3 from working in breast cancer and hope this will lead to the development of new drugs to prevent breast cancer from spreading and treat it if it does. 
MicroRNAs are a newly discovered class of molecules that act as genetic regulators within cells. They control processes involved in cell division and cell death, and have important roles in preventing cancer. We have previously found that estrogen causes production of specific microRNAs that down-regulate the activity of the gene that codes for the estrogen receptor which means that there is never too much estrogenic activity and it is controlled, in a unique feedback loop that we have identified. We now believe that microRNAs act in a similar way in controlling LMTK3 activity which in turn acts directly and indirectly on estrogenic pathways and controls breast cancer growth and survival. We aim to identify which microRNAs regulate LMTK3 and hope to show that in breast cancer these microRNAs are not properly produced, so there is less regulation of LMTK3 activity, and the breast cancer cells continue to divide and respond less well to treatments. If we can turn this process off, or give patients the microRNAs they don't make, we can treat breast cancer and reverse this process. Firstly, we must identify the different types of microRNAs that regulate LMTK3 in breast cancer and understand which factors control microRNA production. This would present exciting new possibilities for diagnosis and patient-specific treatments, and may help us to detect hard-to-diagnose cancer and determine how aggressively a cancer might behave. These microRNAs may, in years to come, also be used as prognostic biomarkers (telling us how long someone will live for) and predictive biomarkers (telling us how to treat patients) in the clinic. Most relevant to this proposal, the miRNAs may help us understand resistance to hormonal therapies, and why some women on drugs like tamoxifen or aromatase inhibitors relapse.

This work will be conducted by Dr. Victoria Harding, a senior registrar in oncology dedicated to pursuing a career as a clinician scientist in order to create a bridge between the laboratory and the clinic and vice versa. This project will be ideal as it involves an array of laboratory techniques enabling her to study cellular processes but also involves the use of tumor tissue obtained from patients with breast cancer that will allow her to correlate her findings in the lab with factors such as patient survival and response to therapies.</gtr:abstractText><gtr:technicalSummary>Aims: 
To establish the role of miRNAs in the regulation and signaling induced by the new oncogenic kinase LMTK3, and to understand their role in estrogenic signaling and tumorigenesis. 
 
Objectives:
1. To identify LMTK3/FOXO3a-regulated miRNAs using the UCSC genome browser, miRNA expression profiling arrays, chromatin immunoprecipitation and luciferase reporter assays. We also wish to establish whether these miRNAs regulate LMTK3 expression post-transcriptionally aiming to reveal an active feedback loop. 
2. To study the effects of miRNA-induced regulation on the direct/indirect actions of LMTK3, such as estrogen receptor-alpha (ERa) regulation, cell proliferation/viability and endocrine resistance. 
3. To assess the clinical relevance of FOXO3a-regulated and/or LMTK3-targeting miRNAs, by correlating levels of pre- and mature miRNAs with LMTK3 and ERa expression, in well characterised patient cohorts (n=1210) with comprehensive survival data. 

Methodology: 
This project uses a range of cell and molecular biology techniques, bioinformatics and tissue handling techniques, which are well established in the host laboratory. 

Scientific and Medical Opportunities 
This proposal derives from the interplay of two recent publications from the host laboratory and aims to elucidate a novel mechanism of LMTK3 regulation. Estrogen driven pathways are crucial to breast tumorigenesis and LMTK3 plays an important role here. We wish to study how the interaction between the ERa and LMTK3 is regulated and controlled by microRNAs, which may help us better understand resistance to hormonal therapies. This work which will not occur in isolation (an LMTK3 based drug discovery strategy has also commenced) has broad and far-reaching basic science strengths, and thus its ultimate impact to patients may not be immediately evident. However, the elucidation of a new regulatory system has the potential to produce broad, fundamental insights into new basic science processes.</gtr:technicalSummary><gtr:potentialImpactText>This proposal aims to make fundamental differences in a highly competitive area, focusing on the interactions between miRNAs, miRNA biogenesis and specific oncogenes, with particular focus on the newly identified oncogenic kinase LMTK3 in breast cancer. As such, we are not aiming at this point to commercially exploit any discoveries. Previous data from the host laboratory reveal a number of open questions regarding the exact mechanism of LMTK3-mediated ERa stability and FOXO3 regulation, many of which we believe we can answer via an understanding of microRNA-(miRNA)-regulated pathways in this system. As the host laboratory (and others) have previously identified the set of miRNAs induced by the ERa in breast cancer, we wish to establish regulation of this kinase by miRNAs. The basic science investigation described above aims to occur alongside a drug discovery program which includes elucidation of the crystal structure of LMTK3 (or at least its kinase domain) with our close collaborators. This endeavour will not be possible without understanding the basic science that connects LMTK3 to the activity of ERa, and miRNAs are likely to be critical here. We would work closely with our collaborators to ensure maximum value from any discoveries but emphasise that at this stage, the PhD proposal focuses on basic science, the benefits of which can take many years to be realised in the clinic.
 
A key feature of this work is its international collaborative nature and the fact that our team is already set up, should funding be available. It has broad and far-reaching basic science strengths, and thus its ultimate impact to people or patients may not be immediately evident. However, the elucidation of a new regulatory system has the potential to have importance across a range of human endeavours.

The specific beneficiaries here are likely to be:

1. Basic science: We aim to elucidate a new pathway of regulation of a new oncogenic kinase. This has benefits for this cross disciplinary work, science and our collaborations in general. We would aim here to continually present and publish our work throughout the grant period and thereafter.

2. Patients: This may, in years to come, lead to prognostic and predictive biomarkers in the clinic, and new therapies specifically designed to overcome endocrine resistance. While primary breast cancer is curable, metastatic breast cancer it is not. While metastatic genes have been discovered, the factors that regulate these have remained unclear and we have now found miRNAs that appear to influence this process, and control it, and we believe this applies to miRNAs that act on LMTK3 which in turn acts directly and indirectly on estrogenic pathways. Ultimately in years to come, if we can understand how and why breast cancer spreads, we can attempt to stop it from doing so with much greater clarity. MicroRNAs are also likely to have utility as prognostic and predictive biomarkers. We have already found that LMTK3 levels are prognostic and predictive. They also teach us how cancer cells divide and spread, and knowing this is also part of the solution to preventing breast cancer from being the major cause of cancer death in women. Most relevant to this proposal, the miRNAs may help us understand resistance to hormonal therapies, and why some women on drugs like tamoxifen or aromatase inhibitors relapse.

3. Training and personnel: The wide variety of techniques employed is likely to be of enormous benefit to the applicant, department and students. The project has broad potential and utility.

In summary, the value and impact of research is not always immediately evident and may take fruition over many years, or longer. Excellent research leads to academic advances across and within disciplines, including significant advances in knowledge, theory and application. This focused proposal aims to further these advances, and lead to major discoveries.</gtr:potentialImpactText><gtr:fund><gtr:end>2017-12-04</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>215579</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Interview for filming company</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BD072DD0-674C-4749-B6EF-3D2A99D2BE45</gtr:id><gtr:impact>Raised awareness of the research our group is undertaking

Unknown at present</gtr:impact><gtr:outcomeId>545bb0f7c64858.09580590</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Personal tutor at University - gave talk to the students</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>DB637988-56E7-4567-AB06-CCD8682D5DD6</gtr:id><gtr:impact>Talk to medical students about academic careers for clinicians

Approached by a few students re summer internships etc</gtr:impact><gtr:outcomeId>545bb16289d3f2.94689310</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Mammosphere production - technique to be published by JOVE</gtr:description><gtr:id>0A6F3717-3031-4A7F-B74C-21D798FF22B1</gtr:id><gtr:impact>Dissemination of technique to others in the field</gtr:impact><gtr:outcomeId>545bb20cbd1192.83169645</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>New method to be filmed by JOVE</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>82A44CBE-E213-476B-A330-52EE719E3C9B</gtr:id><gtr:title>Characterization of the Tyrosine Kinase-Regulated Proteome in Breast Cancer by Combined use of RNA interference (RNAi) and Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) Quantitative Proteomics.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular proteomics : MCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e33acbcfebc59f56dcd3f5a93527f83"><gtr:id>2e33acbcfebc59f56dcd3f5a93527f83</gtr:id><gtr:otherNames>Stebbing J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1535-9476</gtr:issn><gtr:outcomeId>5a6ef308ded006.10872022</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74D13901-47C8-4990-A33C-EE4FF4C7855A</gtr:id><gtr:title>Abstract P4-03-02: Stromal kinome screening identifies a novel regulatory kinase implicated in fibroblast-mediated progression of invasion in triple negative breast cancer tumours</gtr:title><gtr:parentPublicationTitle>Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ded849dc76581ccd5db09db71d7e49da"><gtr:id>ded849dc76581ccd5db09db71d7e49da</gtr:id><gtr:otherNames>Giamas G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a6f535eca16b2.45835318</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE3D4EE3-08CA-410C-8405-68F58012EB23</gtr:id><gtr:title>The prognostic role of circulating tumor cells in heavily pretreated individuals with a low life expectancy.</gtr:title><gtr:parentPublicationTitle>Future oncology (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e33acbcfebc59f56dcd3f5a93527f83"><gtr:id>2e33acbcfebc59f56dcd3f5a93527f83</gtr:id><gtr:otherNames>Stebbing J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1479-6694</gtr:issn><gtr:outcomeId>545b9ce3aa2a15.83313755</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BD60205-265C-4D87-B938-72EFA9791CF2</gtr:id><gtr:title>Patient-derived xenografts for individualized care in advanced sarcoma.</gtr:title><gtr:parentPublicationTitle>Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e33acbcfebc59f56dcd3f5a93527f83"><gtr:id>2e33acbcfebc59f56dcd3f5a93527f83</gtr:id><gtr:otherNames>Stebbing J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0008-543X</gtr:issn><gtr:outcomeId>545b9ce3d72127.63777980</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BAC8461-0882-4221-B634-22D3F1075574</gtr:id><gtr:title>The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin ?1.</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0cd56c5d6f324ffe01776b7518642ba"><gtr:id>d0cd56c5d6f324ffe01776b7518642ba</gtr:id><gtr:otherNames>Xu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn><gtr:outcomeId>5a6f058f6d4748.03486036</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>704E9EE0-8ABE-4D97-90B5-0AF20AB31882</gtr:id><gtr:title>Proteome-wide dataset supporting functional study of tyrosine kinases in breast cancer.</gtr:title><gtr:parentPublicationTitle>Data in brief</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b223c0e7c2300183fb90f842de7677c2"><gtr:id>b223c0e7c2300183fb90f842de7677c2</gtr:id><gtr:otherNames>Angelopoulos N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2352-3409</gtr:issn><gtr:outcomeId>5a6ef23a3819c8.05874147</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAED07C3-9F56-4102-9715-91E0A5DA95AC</gtr:id><gtr:title>Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0642bb27ff8a8366b9c905157c9e459b"><gtr:id>0642bb27ff8a8366b9c905157c9e459b</gtr:id><gtr:otherNames>Wakatsuki T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>5a6f079023fcc3.77733469</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E88746DB-3CA5-4CE5-8CAB-D36E595DBD1C</gtr:id><gtr:title>Sphingosine kinase 1 contributes to leptin-induced STAT3 phosphorylation through IL-6/gp130 transactivation in oestrogen receptor-negative breast cancer.</gtr:title><gtr:parentPublicationTitle>Breast cancer research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a3541e39f0fe5a01d45c286adf82b27"><gtr:id>2a3541e39f0fe5a01d45c286adf82b27</gtr:id><gtr:otherNames>Alshaker H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0167-6806</gtr:issn><gtr:outcomeId>5a6ef1a0612778.38912684</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56B38AAB-B98E-465E-9F40-ECAF445CA512</gtr:id><gtr:title>The p53 miRNA interactome and its potential role in the cancer clinic.</gtr:title><gtr:parentPublicationTitle>Epigenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5030cde49f5b6dba14f2ed66b8a6ce6f"><gtr:id>5030cde49f5b6dba14f2ed66b8a6ce6f</gtr:id><gtr:otherNames>Krell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1750-192X</gtr:issn><gtr:outcomeId>pm_22876_26_23895654</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEB31CC8-1929-4D7E-8889-3D2A6596E5FF</gtr:id><gtr:title>MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acaf30a8186ef9eb97059a8c8aaae958"><gtr:id>acaf30a8186ef9eb97059a8c8aaae958</gtr:id><gtr:otherNames>Frampton AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>pm_22876_26_24120476</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>950BDD90-3A69-4F42-95D8-5FCC7B35FB4B</gtr:id><gtr:title>Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERa-positive advanced breast cancer.</gtr:title><gtr:parentPublicationTitle>The pharmacogenomics journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/702c663817c8f6b095f40f16b78430a1"><gtr:id>702c663817c8f6b095f40f16b78430a1</gtr:id><gtr:otherNames>Benhaim L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1470-269X</gtr:issn><gtr:outcomeId>5a6ef2b3c74456.84091371</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>176758B6-A16A-4C30-B4F8-04E250598322</gtr:id><gtr:title>The role of TP53 in miRNA loading onto AGO2 and in remodelling the miRNA-mRNA interaction network.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5030cde49f5b6dba14f2ed66b8a6ce6f"><gtr:id>5030cde49f5b6dba14f2ed66b8a6ce6f</gtr:id><gtr:otherNames>Krell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>56dcba05d18171.11511545</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9435C795-4EB3-4196-875E-64118ED845A7</gtr:id><gtr:title>'Being there' for women with metastatic breast cancer: a pan-European patient survey.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d07be128b0127bb5735551c56cd8bfa8"><gtr:id>d07be128b0127bb5735551c56cd8bfa8</gtr:id><gtr:otherNames>Harding V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_22876_26_24002595</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A60C4CB-BCB0-4900-8A69-4DA9B915FAA7</gtr:id><gtr:title>Growth arrest-specific transcript 5 associated snoRNA levels are related to p53 expression and DNA damage in colorectal cancer.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5030cde49f5b6dba14f2ed66b8a6ce6f"><gtr:id>5030cde49f5b6dba14f2ed66b8a6ce6f</gtr:id><gtr:otherNames>Krell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>545b9ce37f4aa2.34362644</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E9E6305-5D60-4217-A4D1-D8B9043DD264</gtr:id><gtr:title>Abstract 1606: Global mapping of tyrosine kinase signalling in breast cancer by combined use of RNAi and SILAC quantitative proteomics</gtr:title><gtr:parentPublicationTitle>Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bde23452702f3d087e5f35cb87dd0e1"><gtr:id>1bde23452702f3d087e5f35cb87dd0e1</gtr:id><gtr:otherNames>Zhang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5a6f534475e2c9.82385540</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B5D1C58-D8D2-4D32-9EAA-171756B33316</gtr:id><gtr:title>SILAC-based phosphoproteomics reveals an inhibitory role of KSR1 in p53 transcriptional activity via modulation of DBC1.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bde23452702f3d087e5f35cb87dd0e1"><gtr:id>1bde23452702f3d087e5f35cb87dd0e1</gtr:id><gtr:otherNames>Zhang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>5a6ef21d512af4.18384426</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A44F50C-D487-45A5-AD61-EC8C28C94EFC</gtr:id><gtr:title>LMTK3 Represses Tumor Suppressor-like Genes through Chromatin Remodeling in Breast Cancer.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0cd56c5d6f324ffe01776b7518642ba"><gtr:id>d0cd56c5d6f324ffe01776b7518642ba</gtr:id><gtr:otherNames>Xu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>5a6ef27aae9517.15586398</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4019046E-3330-4351-834F-A028A5B874A2</gtr:id><gtr:title>Noncoding RNAs and the control of hormonal signaling via nuclear receptor regulation.</gtr:title><gtr:parentPublicationTitle>Journal of molecular endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/665e43705d45884e0ba5e526a50c7a80"><gtr:id>665e43705d45884e0ba5e526a50c7a80</gtr:id><gtr:otherNames>Ottaviani S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0952-5041</gtr:issn><gtr:outcomeId>545b9ce355dee3.29487614</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC29BDB0-BA83-4F84-93CC-66762B3F7E7A</gtr:id><gtr:title>Abstract 4213: Evaluation of LMTK3 expression and tumor phenotype in estrogen-dependent colorectal cancer</gtr:title><gtr:parentPublicationTitle>Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b440321c988e1106ed6e5832b280fb2"><gtr:id>4b440321c988e1106ed6e5832b280fb2</gtr:id><gtr:otherNames>Magturo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5a6f53448a6b70.96656211</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C34BC63-F95E-4CE2-9CAF-824AB6655DF0</gtr:id><gtr:title>Broader implications of SILAC-based proteomics for dissecting signaling dynamics in cancer.</gtr:title><gtr:parentPublicationTitle>Expert review of proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bde23452702f3d087e5f35cb87dd0e1"><gtr:id>1bde23452702f3d087e5f35cb87dd0e1</gtr:id><gtr:otherNames>Zhang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1478-9450</gtr:issn><gtr:outcomeId>5a6f0773708c03.18405445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F2A1BF5-BB7E-43F1-86C4-5F7E2C8EFAC9</gtr:id><gtr:title>TP53 regulates miRNA association with AGO2 to remodel the miRNA-mRNA interaction network.</gtr:title><gtr:parentPublicationTitle>Genome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5030cde49f5b6dba14f2ed66b8a6ce6f"><gtr:id>5030cde49f5b6dba14f2ed66b8a6ce6f</gtr:id><gtr:otherNames>Krell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1088-9051</gtr:issn><gtr:outcomeId>56dcba06026538.93225839</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B6E028B-2506-4A9D-A84E-9EF16498EEC6</gtr:id><gtr:title>Novel cancer therapies: treatments driven by tumour biology.</gtr:title><gtr:parentPublicationTitle>Postgraduate medical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c82fa4fdc19382fc8868ea5637b29a95"><gtr:id>c82fa4fdc19382fc8868ea5637b29a95</gtr:id><gtr:otherNames>Ramaswami R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0032-5473</gtr:issn><gtr:outcomeId>pm_22876_26_24129032</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C62BAE98-C3F7-41B0-BCFA-281A15A1B3E2</gtr:id><gtr:title>Abstract P6-04-15: The involvement of LMTK3 in endocrine resistance is mediated via multiple signaling pathways</gtr:title><gtr:parentPublicationTitle>Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ded849dc76581ccd5db09db71d7e49da"><gtr:id>ded849dc76581ccd5db09db71d7e49da</gtr:id><gtr:otherNames>Giamas G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5a6f5343ed4ee1.08344725</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD62F9AC-980C-4BC9-AD5F-22668A247A10</gtr:id><gtr:title>Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway.</gtr:title><gtr:parentPublicationTitle>Breast cancer research : BCR</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a3541e39f0fe5a01d45c286adf82b27"><gtr:id>2a3541e39f0fe5a01d45c286adf82b27</gtr:id><gtr:otherNames>Alshaker H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1465-5411</gtr:issn><gtr:outcomeId>5a6f060d6c5117.50262943</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FAFB756-AAD2-41B9-B7EC-FFAAC787C47B</gtr:id><gtr:title>TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86a698de9cb1f2e82bb28891272d82bc"><gtr:id>86a698de9cb1f2e82bb28891272d82bc</gtr:id><gtr:otherNames>Pinato DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>5a6ef2471e1d32.46436343</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A94B6B9-BBB8-442C-B7AC-41D6EF845EC5</gtr:id><gtr:title>Crystals and cancer: good vibrations or bad intentions?</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d07be128b0127bb5735551c56cd8bfa8"><gtr:id>d07be128b0127bb5735551c56cd8bfa8</gtr:id><gtr:otherNames>Harding V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>545b9ce42e6764.56068091</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DC52A5F-B0E1-4C7C-9C0A-DA93BB624F0F</gtr:id><gtr:title>Abstract 185: Role of phosphorylation in Lmtk3 activation and its contribution in breast cancer progression</gtr:title><gtr:parentPublicationTitle>Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c5eb9141887bc70fa7331db939fc24a"><gtr:id>7c5eb9141887bc70fa7331db939fc24a</gtr:id><gtr:otherNames>Lucchiari G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>5a6f53455c95c1.57014719</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90D206A8-1599-4A61-AAB4-47B71CCFFE00</gtr:id><gtr:title>Abstract 5268: The expression of lemur tyrosine kinase-3 in high grade pediatric tumors</gtr:title><gtr:parentPublicationTitle>Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f032b7fd581907b81f6ddc39f295916b"><gtr:id>f032b7fd581907b81f6ddc39f295916b</gtr:id><gtr:otherNames>Mazarakis N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5a6f5361837977.15737903</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1088BF7B-A596-4DA7-98E8-7364117421C8</gtr:id><gtr:title>Emerging roles of competing endogenous RNAs in cancer: insights from the regulation of PTEN.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f2bef4bfd0ffd0920fad8c50ac105d0"><gtr:id>1f2bef4bfd0ffd0920fad8c50ac105d0</gtr:id><gtr:otherNames>de Giorgio A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn><gtr:outcomeId>pm_22876_26_23918803</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90149988-8831-4FBB-B7F8-7CC393B566A7</gtr:id><gtr:title>LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5.</gtr:title><gtr:parentPublicationTitle>Cancer letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f42df0eb4ddcddd650ff75bdff9d79b7"><gtr:id>f42df0eb4ddcddd650ff75bdff9d79b7</gtr:id><gtr:otherNames>Jacob J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0304-3835</gtr:issn><gtr:outcomeId>56dcba062c8e11.59618610</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88BF0DCC-C3EE-4227-91F7-EECC30A7F86D</gtr:id><gtr:title>Brain metastases associated with germ cell tumors may be treated with chemotherapy alone.</gtr:title><gtr:parentPublicationTitle>Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10749278d229f2e2a44498642b337cee"><gtr:id>10749278d229f2e2a44498642b337cee</gtr:id><gtr:otherNames>Hardt A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0008-543X</gtr:issn><gtr:outcomeId>545b9ce4091a55.36196853</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A5CCD43-8296-498E-BFEF-35DE3078E40E</gtr:id><gtr:title>The need for multidisciplinarity in specialist training to optimize future patient care.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/723821d65d193419cd64ae4e1bf685f6"><gtr:id>723821d65d193419cd64ae4e1bf685f6</gtr:id><gtr:otherNames>Tree AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-4774</gtr:issn><gtr:outcomeId>58c675229791b1.46414237</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21FC0031-598E-4734-8BA7-C5DB1C0AD60E</gtr:id><gtr:title>Downregulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase 1 and breast cancer cell proliferation.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51c0cc3a0d067cfafa22377624726f64"><gtr:id>51c0cc3a0d067cfafa22377624726f64</gtr:id><gtr:otherNames>Pinho FG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pm_22876_26_23928990</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE947380-9190-4B2E-AB06-7299BB6D6C03</gtr:id><gtr:title>Abstract 64: Identification of novel kinases involved in Estrogen receptor-a (ERa) signalling and the development of endocrine resistance in breast cancer</gtr:title><gtr:parentPublicationTitle>Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ded849dc76581ccd5db09db71d7e49da"><gtr:id>ded849dc76581ccd5db09db71d7e49da</gtr:id><gtr:otherNames>Giamas G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5a6f5348165823.58867385</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F128D00D-9C2B-4459-AA91-B8A87FF2C0BE</gtr:id><gtr:title>Abstract 3794: The role of LMTK3 in breast cancer cell growth and invasion.</gtr:title><gtr:parentPublicationTitle>Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0cd56c5d6f324ffe01776b7518642ba"><gtr:id>d0cd56c5d6f324ffe01776b7518642ba</gtr:id><gtr:otherNames>Xu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5a6f5344612e17.47945274</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>192CF17C-358D-4DB3-914D-47E59E8140EE</gtr:id><gtr:title>The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b076cba8518e7236d99102cc39c7737"><gtr:id>0b076cba8518e7236d99102cc39c7737</gtr:id><gtr:otherNames>Badreldin W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56dcba05abac10.37676344</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L000172/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>